SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.

Lancet Diabetes Endocrinol · 2018

Last updated 2026-05-28

Journal	Lancet Diabetes Endocrinol, 2018
Citations	10
Relative citation ratio	0.29
NIH percentile	18
Molecules	—
Conditions studied	Type 2 Diabetes, Cardiovascular Risk Reduction, Obesity, Chronic Kidney Disease

Full record and abstract on PubMed 29483059 ↗